News | September 21, 2009

IBA, Aposense to Co-Market New PET Agent

September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.

The new agent is a small molecule radiotracer which allows the imaging of apoptosis, a fundamental biological process of controlled cell death, from the early stages of the death process. Given the broad, cross disease role of apoptosis in a wide range of medical disorders, molecular imaging with [18F]-ML-10 is expected to play an important role in early detection of disease, monitoring of disease course, assessment of effect of treatment or development of novel therapies. In particular, [18F]-ML-10 may assist oncologists in evaluating tumor response to treatment much earlier than conventional imaging modalities such as CT or MRI. This may allow clinicians to identify earlier the most effective treatment within their therapeutic arsenal and provide personalized, safer and more cost-effective care. Among other clinical fields of potential applications of [18F]-ML-10 are cardiology and neurology.
[18F]-ML-10 illustrates the capability of nuclear molecular imaging to become a central discipline in healthcare and to deliver the clinical and economic benefits of Personalized Medicine.

The long-term, global agreement includes the collaboration and joint-funding by IBA and Aposense of phase III and subsequent clinical development of [18F]-ML-10. In addition, the companies will jointly market and sell [18F]-ML-10, with IBA primarily focusing on its core PET imaging and nuclear medicine market, and Aposense marketing to the referring clinical specialist market. Aposense will manufacture the proprietary ML-10 precursor and IBA will 18F-label and distribute the final drug product to clinical sites through its global network of PET radio-pharmacies. IBA and Aposense will share in revenue and development costs. Specific financial terms were not disclosed. Multi-center phase II clinical trials of [18F]-ML-10 are underway in a number of leading cancer centers in the United States, and are expected to be completed in 2010, to be followed by phase 3 trials during 2011/2012 for obtaining regulatory approvals.

This agreement expands the relationship established between IBA and Aposense in August 2008, when they entered into an agreement for 18F-labeling and distributing of ML-10 by IBA for Aposense’s multi-center clinical trials.

For more information: www.iba-worldwide.com and www.nst.co.il

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init